


## Development of an Effective Scalable Synthesis of Lumicitabine

Sébastien Lemaire.

Discovery, Product Development and Supply (DPDS)  
Janssen Pharmaceutical Companies of Johnson & Johnson  
Turnhoutseweg 30, B-2340 Beerse  
Belgium  
*slemaire@its.jnj.com*

Modified nucleosides continue to hold a central position in the chemotherapy of cancer and viral diseases such as Hepatitis C Virus (HCV) and Respiratory Syncytial Virus (RSV). In particular, 2'-modified nucleosides play an important role in research to understand the detailed molecular basis of RNA function. In connection with our internal program in the antiviral area, we needed to prepare a series of modified nucleosides to support clinical trials. In this presentation, we will highlight the challenges to improve the Lumicitabine (ALS-8176)<sup>1</sup> synthesis from a medical chemistry route to a manufacturing process capable of supporting Phase 3 clinical studies.



1. Wang, G.; Beigelman, L. *et al. J. Med. Chem.* **2015**, *58*, 1862–1878.